Prestige Biopharma - Dr Reddy's Partnership To Commercialise Trastuzumab Biosimilar

KUALA LUMPUR, Dec 9 -- Prestige BioPharma Ltd and Dr Reddy’s Laboratories Ltd (Dr Reddy’s) have announced entering into a binding agreement for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar at select countries in Latin America and Southeast Asia.

Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin® and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer.

Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

The licence agreement grants Dr Reddy’s the exclusive rights to commercialise the proposed biosimilar in select countries in Latin America and Southeast Asia.

Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.

In a statement, Prestige BioPharma CEO, Lisa S. Park said: “We are delighted to establish a partnership with Dr Reddy’s for key Latin American and Southeast Asian markets. Dr Reddy’s is the ideal partner to commercialise our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.”

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr Reddy’s, said: “In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need.

“Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets.”

For more information, visit www.prestigebio.com.

-- BERNAMA